Company Profile
Chengdu Aixing Biotechnology Co., Ltd. is a China-based manufacturer of homogeneous chemiluminescence POCT systems, headquartered in Chengdu, Sichuan, China. Founded in April 2013, the company operates as an independent private entity, serving clinical laboratories, emergency departments, and point-of-care settings across China. The company holds National High-Tech Enterprise status and is recognized as a Specialized and Innovative SME in Sichuan Province.
Core Products and Technologies
POCT Analyzers
• LIA-12 System: The world's first homogeneous chemiluminescence POCT platform based on LOCI technology, featuring wash-free, substrate-free operation with CV＜5%
• Next-Gen Automated Analyzer: Fully automated homogeneous chemiluminescence immunoassay analyzer certified in 2023, supporting higher throughput for clinical labs
Diagnostic Reagents
• Cardiac Markers: cTnI, CK-MB, Myoglobin, NT-proBNP assays
• Inflammation Markers: PCT, CRP, IL-6, SAA assays
• Gastric Function: PGI, PGII assays for gastric screening
• Renal Function: CysC assay
• Coagulation: D-Dimer assay
• Glycemic Monitoring: HbA1c assay (certified 2022)
Market Position & Certifications
Aixing Bio holds a pioneering position in China's homogeneous chemiluminescence POCT segment, competing with Chemclin Diagnostics (688468.SH) and Wondfo Biotech. Key strengths include:
• 10+ years of Chinese IVD engineering heritage with core raw materials fully self-developed
• LOCI-based Homogeneous Technology: Wash-free, magnetic-bead-free chemiluminescence with high precision and low maintenance
• Regulatory compliance: NMPA Class II medical device registrations (20+ assays), CE marked (7 products since 2021)
• Clinical adoption: Deployed in 17+ hospital departments including clinical labs, emergency units, and ICUs
Corporate Timeline
2013 — Founded in Chengdu by IVD scientists with 20+ years of R＆D experience
2016 — Completed Series A financing from Zhongyuan Bio and Xinjin Shifeng Medical
2017 — Completed Series A+ financing from YuanSheng Venture Capital; production base built in Pidu District
2018 — LIA-12 recognized as Sichuan's first Class II innovative IVD device; system launched
2019 — Obtained production license; first LIA-12 installation completed
2020 — Completed Series B financing from Lingxian Health (Yushan Capital); launched COVID-19 antibody kits
2021 — Certified as National High-Tech Enterprise; 7 products received CE marking
2022 — HbA1c assay certified in December
2023 — 10 additional product registrations approved in March; fully automated analyzer certified in April
Target Markets & Applications
• Emergency and Critical Care: Cardiac marker panels for rapid triage and chest-pain evaluation
• Clinical Laboratories: Inflammation and infection marker quantification for sepsis monitoring
• Gastroenterology: Gastric function screening via pepsinogen assays
• Nephrology and Coagulation: Renal function and D-Dimer testing for ICU patients
• Diabetes Management: HbA1c testing for endocrinology and primary care
Contact Information
Global Headquarters
Address: No. 269 Gangtong North 3rd Road, Pidu District, Chengdu, Sichuan, China
Tel: +86-28-64165468
Email: ix@ixingbio.com
Website: ixingbio.com
Corporate Structure
Chengdu Aixing Biotechnology Co., Ltd. operates as an independent private enterprise with no publicly traded parent company.
Legal Representative: Bao Dequan
Registered Capital: RMB 13.294886 million
Unified Social Credit Code: 915101000643341495
Investor Relations: Not applicable — privately held company with no publicly traded stock.
